The emerging relevance of the cysteine protease Cathepsin S in disease


Autoria(s): Small, Donna M.; Burden, Roberta E.; Scott, Christopher J.
Data(s)

01/06/2011

Identificador

http://pure.qub.ac.uk/portal/en/publications/the-emerging-relevance-of-the-cysteine-protease-cathepsin-s-in-disease(a03faa14-885e-4ea6-bedb-202f4448fafd).html

http://dx.doi.org/10.1007/s12018-011-9095-5

Idioma(s)

eng

Direitos

info:eu-repo/semantics/restrictedAccess

Fonte

Small , D M , Burden , R E & Scott , C J 2011 , ' The emerging relevance of the cysteine protease Cathepsin S in disease ' Clinical Reviews in Bone and Mineral Metabolism , vol 9 , no. 2 , pp. 122-132 . DOI: 10.1007/s12018-011-9095-5

Palavras-Chave #/dk/atira/pure/subjectarea/asjc/1300/1310 #Endocrinology #/dk/atira/pure/subjectarea/asjc/2700/2712 #Endocrinology, Diabetes and Metabolism #/dk/atira/pure/subjectarea/asjc/2700/2732 #Orthopedics and Sports Medicine
Tipo

article

Resumo

Cathepsin S is a lysosomal cysteine protease that has been shown to play a key role in MHC class II antigen presentation. Consequently, it has been extensively evaluated as a therapeutic target in autoimmune diseases, such as rheumatoid arthritis and psoriasis. Additionally, clinical and mechanistic evidence is emerging, revealing its inappropriate expression and secretion in a wide range of disease states including atherosclerosis and tumourigenesis. This review covers the known role and consequences of cathepsin S activity in these pathological disorders, highlighting various studies that have demonstrated its utility as a therapeutic target. This review also examines challenges that exist towards the development of agents that specifically target this protease and discusses the studies to date that have applied cathepsin S inhibitors in disease models.